|1.||Moreno, Santiago: 1 article (11/2015)|
|2.||Clemente, Maria Isabel: 1 article (11/2015)|
|3.||Álvarez, Susana: 1 article (11/2015)|
|4.||Muñoz-Fernández, Maria Ángeles: 1 article (11/2015)|
|5.||Díaz, Laura: 1 article (11/2015)|
|6.||García-Alonso, Dolores: 1 article (11/2015)|
|7.||Martínez-Bonet, Marta: 1 article (11/2015)|
|8.||Muñoz, Eduardo: 1 article (11/2015)|
|9.||Khaw, Wong Yu: 1 article (01/2013)|
|10.||Turaka, Kiran: 1 article (01/2013)|
11/01/2006 - "The Food and Drug Administration has approved Atripla Tablets, a fixed-dose combination of three widely used antiretroviral drugs in a single tablet for the treatment of HIV-1 infection in adults. "
11/01/2015 - "BRY alone or in combination with maraviroc (MVC)/Atripla (ATP) was tested for its capacity to reactivate latent virus and inhibit new infections. "
01/01/2009 - "Tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) are the three components of the once-daily, single tablet regimen (Atripla) for treatment of HIV-1 infection. "
|2.||HIV Infections (HIV Infection)
07/01/2007 - "The latter has also been approved, in combination with emtricitabine (Truvada), and in combination with emtricitabine and efavirenz (Atripla((R))) for the treatment of HIV infections. "
01/01/2007 - "Given the information that has been acquired on the therapeutic use (efficacy, safety) of tenofovir disoproxil fumarate over the past five years, it would now seem mandatory to further consider the prophylactic use of TDF [and its combination with emtricitabine (Truvada) and/or Atripla], as a single daily pill to prevent HIV infection."
|3.||Acquired Immunodeficiency Syndrome (AIDS)
|3.||tenofovir disoproxil (Viread)
|6.||Adenosine Triphosphate (ATP)